Maina Bhaman
Partner, Sofinnova Partners - Capital Strategy
Maina is a Partner in the Sofinnova Capital Strategy. She joined us in 2018, bringing an extensive network and a long track record as a successful healthcare investor.
Prior to joining Sofinnova, she was director of healthcare investment at Touchstone Innovations (formerly Imperial Innovations) in London, where she led and co-led investments in the UK.
Maina’s interest in biotechnology goes back to her childhood. “I've wanted to be in biotech since I was 16 years old,” she said. “It was the early days, when Amgen and Genentech were first in the news, and it just sounded cool to me.”
Before turning to investing, Maina worked in the R&D teams of several UK and US biotech companies, including Celltech, Oxford GlycoSciences, Chimeric Therapies and GeneMedicine.
Her current investments include Sitryx Therapeutics Ltd, Mironid Ltd, Myricx Bio, Mediar Therapeutics, Enyo Pharma, Nuage Therapeutics, and Catamaran Bio.
Maina holds a Bachelor's in Science degree from the University of Texas at Austin and an MBA from the Imperial Business School.
“I've wanted to be in biotech since I was 16 years old. It was the early days, when Amgen and Genentech were first in the news, and it just sounded cool to me.”
Sectors
Biopharmaceuticals & Medical Devices
